Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study

Abstract Purpose The antibody–drug conjugate trastuzumab deruxtecan has proven to be not only efficient in patients with HER2+ breast cancers (BC), but also in those patients with so-called HER2-low BC. HER2-low tumors are well described in the general BC population, but not in patients with invasiv...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:Breast Cancer Research
المؤلفون الرئيسيون: Karen Van Baelen, Ha-Linh Nguyen, François Richard, Gitte Zels, Maria Margarete Karsten, Guilherme Nader-Marta, Peter Vermeulen, Luc Dirix, Adam David Dordevic, Evandro de Azambuja, Denis Larsimont, Marion Maetens, Elia Biganzoli, Hans Wildiers, Ann Smeets, Ines Nevelsteen, Patrick Neven, Giuseppe Floris, Christine Desmedt
التنسيق: مقال
اللغة:الإنجليزية
منشور في: BMC 2025-06-01
الموضوعات:
Invasive lobular carcinoma
HER2-low
Clinicopathological features
Survival
الوصول للمادة أونلاين:https://doi.org/10.1186/s13058-025-02058-x

الانترنت

https://doi.org/10.1186/s13058-025-02058-x

مواد مشابهة